{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T16:47:55Z","timestamp":1791650875421,"version":"4.3.4"},"reference-count":29,"publisher":"Pharmaceutical Society of Japan","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological & Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2017]]},"DOI":"10.1248\/bpb.b16-01001","type":"journal-article","created":{"date-parts":[[2017,4,30]],"date-time":"2017-04-30T22:07:47Z","timestamp":1493590067000},"page":"698-702","source":"Crossref","is-referenced-by-count":12,"title":["Control of Constipation in Patients Receiving CHOP or CHOP-Like Chemotherapy Regimens for Non-Hodgkin\u2019s Lymphoma"],"prefix":"10.1248","volume":"40","author":[{"given":"Hiroko","family":"Hayashi","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Gifu University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Gifu University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Ohata","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Gifu University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Ishihara","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Gifu University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushi","family":"Kubota","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Gifu University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Gifu University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhei","family":"Shibata","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, Gifu University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Nakamura","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, Gifu University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiko","family":"Nakamura","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, Gifu University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Kitagawa","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, Gifu University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Tsurumi","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, Gifu University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahito","family":"Shimizu","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, Gifu University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Itoh","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Gifu University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","unstructured":"1) Lev\u00eaque D, Jehl F. Molecular pharmacokinetics of catharanthus (vinca) alkaloids. J. Clin. Pharmacol., 47, 579\u2013588 (2007)."},{"key":"2","unstructured":"2) Owellen RJ, Hartke CA, Dickerson RM, Hains FO. Inhibition of tubulin-microtubule polymerization by drugs of the vinca alkaloid class. Cancer Res., 36, 1499\u20131502 (1976)."},{"key":"3","unstructured":"3) Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin\u2019s lymphoma. N. Engl. J. Med., 328, 1002\u20131006 (1993)."},{"key":"4","unstructured":"4) Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med., 346, 235\u2013242 (2002)."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, Solal-Celigny P, Offner F, Walewski J, Raposo J, Jack A, Smith P. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood, 105, 1417\u20131423 (2005).","DOI":"10.1182\/blood-2004-08-3175"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Kasahara S, Hara T, Tsurumi H, Goto N, Kitagawa J, Kanemura N, Yoshikawa T, Goto H, Fukuno K, Yamada T, Sawada M, Takahashi T, Takami T, Moriwaki H. Phase II study of the tetrahydropyranyl adriamycin-cyclophosphamide, vincristine, and prednisolone regimen combined with rituximab as first-line treatment for elderly patients with diffuse large B-cell lymphoma. Leuk. Lymphoma, 52, 629\u2013634 (2011).","DOI":"10.3109\/10428194.2011.555024"},{"key":"7","unstructured":"7) Windebank AJ, Grisold W. Chemotherapy-induced neuropathy. J. Peripher. Nerv. Syst., 13, 27\u201346 (2008)."},{"key":"8","unstructured":"8) Utsu Y, Takaishi K, Inagaki S, Arai H, Yuasa H, Masuda S, Matsuura Y, Aotsuka N, Wakita H. Influence of dose reduction of vincristine in R-CHOP on outcomes of diffuse large B cell lymphoma. Ann. Hematol., 95, 41\u201347 (2016)."},{"key":"9","unstructured":"9) Toghill PJ, Burke JD. Death from paralytic ileus following vincristine therapy. Postgrad. Med. J., 46, 330\u2013331 (1970)."},{"key":"10","unstructured":"10) Shaw RK, Bruner JA. Clinical evaluation of vincristine (M.S.C.-67574). Cancer Chemother. Rep., 42, 45\u201348 (1964)."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Martin J, Compston N. Vincristine sulphate in the treatment of lymphoma and leukaemia. Lancet, 282, 1080\u20131083 (1963).","DOI":"10.1016\/S0140-6736(63)92855-1"},{"key":"12","unstructured":"12) Yasu T, Ohno N, Kawamata T, Kurokawa Y. Vincristine-induced paralytic ileus during induction therapy of treatment protocols for acute lymphoblastic leukemia in adult patients. Int. J. Clin. Pharmacol. Ther., 54, 471\u2013473 (2016)."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Legha SS. Vincristine neurotoxicity. Pathophysiology and management. Med. Toxicol., 1, 421\u2013427 (1986).","DOI":"10.1007\/BF03259853"},{"key":"14","unstructured":"14) Okada N, Hanafusa T, Sakurada T, Teraoka K, Kujime T, Abe M, Shinohara Y, Kawazoe K, Minakuchi K. Risk factors for early-onset peripheral neuropathy caused by vincristine in patients with a first administration of R-CHOP or R-CHOP-like chemotherapy. J. Clin. Med. Res., 6, 252\u2013260 (2014)."},{"key":"15","unstructured":"15) Kagami Y, Itoh K, Tobinai K, Fukuda H, Mukai K, Chou T, Mikuni C, Kinoshita T, Fukushima N, Kiyama Y, Suzuki T, Sasaki T, Watanabe Y, Tsukasaki K, Hotta T, Shimoyama M, Ogura M, Lymphoma Study Group of the Japan Clinical Oncology Group. Phase II study of cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) therapy for newly diagnosed patients with low- and low-intermediate risk, aggressive non-Hodgkin\u2019s lymphoma: final results of the Japan Clinical Oncology Group Study, JCOG9508. Int. J. Hematol., 96, 74\u201383 (2012)."},{"key":"16","unstructured":"16) Kang HJ, Kim WS, Kim SJ, Lee JJ, Yang DH, Kim JS, Lee SR, Lee GW, Kim HJ, Kim HY, Oh SY, Kim HC, Eom HS, Chung J, Park J, Suh C, Ryoo BY. Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study. Ann. Hematol., 91, 543\u2013551 (2012)."},{"key":"17","unstructured":"17) Ocean AJ, Vahdat LT. Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies. Support. Care Cancer, 12, 619\u2013625 (2004)."},{"key":"18","unstructured":"18) Berm\u00fadez M, Fuster JL, Llinares E, Galera A, Gonzalez C. Itraconazole-related increased vincristine neurotoxicity: case report and review of literature. J. Pediatr. Hematol. Oncol., 27, 389\u2013392 (2005)."},{"key":"19","unstructured":"19) Ishihara M, Ikesue H, Matsunaga H, Suemaru K, Kitaichi K, Suetsugu K, Oishi R, Sendo T, Araki H, Itoh Y, Japanese Study Group for the Relief of Opioid-induced Gastrointestinal Dysfunction. A multi-institutional study analyzing effect of prophylactic medication for prevention of opioid-induced gastrointestinal dysfunction. Clin. J. Pain, 28, 373\u2013381 (2012)."},{"key":"20","unstructured":"20) Lindberg JS, Zobitz MM, Poindexter JR, Pak CY. Magnesium bioavailability from magnesium citrate and magnesium oxide. J. Am. Coll. Nutr., 9, 48\u201355 (1990)."},{"key":"21","unstructured":"21) Yamasaki M, Funakoshi S, Matsuda S, Imazu T, Takeda Y, Murakami T, Maeda Y. Interaction of magnesium oxide with gastric acid secretion inhibitors in clinical pharmacotherapy. Eur. J. Clin. Pharmacol., 70, 921\u2013924 (2014)."},{"key":"22","unstructured":"22) Ibuka H, Ishihara M, Suzuki A, Kagaya H, Shimizu M, Kinosada Y, Itoh Y. Antacid attenuates the laxative action of magnesia in cancer patients receiving opioid analgesic. J. Pharm. Pharmacol., 68, 1214\u20131221 (2016)."},{"key":"23","unstructured":"23) Izzo AA, Gaginella TS, Mascolo N, Capasso F. Nitric oxide as a mediator of the laxative action of magnesium sulphate. Br. J. Pharmacol., 113, 228\u2013232 (1994)."},{"key":"24","unstructured":"24) Vu MK, Nouwens MA, Biemond I, Lamers CB, Masclee AA. The osmotic laxative magnesium sulphate activates the ileal brake. Aliment. Pharmacol. Ther., 14, 587\u2013595 (2000)."},{"key":"25","unstructured":"25) Ikarashi N, Ushiki T, Mochizuki T, Toda T, Kudo T, Baba K, Ishii M, Ito K, Ochiai W, Sugiyama K. Effects of magnesium sulphate administration on aquaporin 3 in rat gastrointestinal tract. Biol. Pharm. Bull., 34, 238\u2013242 (2011)."},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Weisinger JR, Bellorin-Font E. Magnesium and phosphorus. Lancet, 352, 391\u2013396 (1998).","DOI":"10.1016\/S0140-6736(97)10535-9"},{"key":"27","unstructured":"27) Onishi S, Yoshino S. Catharticinduced fatal hypermagnesemia in the elderly. Intern. Med., 45, 207\u2013210 (2006)."},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Saito N. In\ufb02uence of impaired renal function and magnesium oxide administration on serum magnesium levels in elderly inpatients. Nippon Ronen Igakkai Zasshi, 48, 263\u2013270 (2011).","DOI":"10.3143\/geriatrics.48.263"},{"key":"29","unstructured":"29) Weng YM, Chen SY, Chen HC, Yu JH, Wang SH. Hypermagnesemia in a constipated female. J. Emerg. Med., 44, e57\u2013e60 (2013)."}],"container-title":["Biological & Pharmaceutical Bulletin","Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/40\/5\/40_b16-01001\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,22]],"date-time":"2019-09-22T15:34:09Z","timestamp":1569166449000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/40\/5\/40_b16-01001\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b16-01001","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}